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The many roads to cross-presentation
 
Tom A.M. Groothuis and Jacques Neefjes
 
Cross-presentation of extracellular antigens by MHC class I molecules is 
required for priming cytotoxic T lymphocytes (CTLs) at locations remote from 
the site of infection. Various mechanisms have been proposed to explain cross-
presentation. One such mechanism involves the fusion of the endoplasmic 
reticulum (ER) with the endosomal-phagosomal system, in which the machinery 
required for peptide loading of MHC class I molecules is introduced directly 
into the phagosome. Here, we discuss the evidence for and against the ER-
phagosome concept as well as other possible mechanisms of cross-presentation.
 
The scientific community warmly
receives data that support new theories
addressing major problems in a field.
These theories can sometimes become
dogma—textbook knowledge—even
when based on inconclusive data. Such
data are difficult to correct with essen-
tially negative results, and such results
equally are difficult to publish. A recent
publication by Touret et al. (1) is an ex-
ception to this rule. In this study, the
concept of ER–phagosome fusion was
tested and refuted, leaving open several
alternative routes for cross-presentation.
Here we discuss recent studies on the bi-
ology of cross-presentation and explain
why the ER–phagosome mechanism is
unlikely to contribute to this process.
 
Classical and cross-presentation by MHC 
class I molecules
 
Cross-presentation is the process by
which extracellular antigens, which are
normally presented in association with
MHC class II molecules, are instead
presented by MHC class I molecules.
This differs from the classical MHC
class I processing pathway in which
MHC class I molecules present antigens
that are synthesized within the cell.
Classical MHC class I antigen presenta-
tion begins with the degradation of
intracellularly synthesized proteins by
the proteasome. Only a fraction of the
peptide fragments that result from this
degradation survives complete destruc-
tion and is transported into the ER by
the peptide transporter TAP (transporter
associated with antigen presentation)
(2). In the ER, the peptides are loaded
onto newly synthesized MHC class I
molecules, and these complexes are then
transported to the cell surface (3). In
contrast, the MHC class II processing
pathway is dedicated to the presentation
of exogenous and self-antigens that are
degraded in the endocytic pathway.
The proteases involved in endocytic
degradation  (cathepsins) are different
than those used in the MHC class I
pathway. Peptides are formed as inter-
mediates during late endosomal protein
degradation and are loaded onto MHC
class II molecules in a reaction catalyzed
by the chaperone protein HLA-DM
before transport to the plasma membrane
(4). MHC class I and MHC class II mol-
ecules thus sample antigenic information
from different sources, intracellular and
extracellular antigens, respectively. A
major exception occurs during cross-
presentation.
In vivo, DCs—the major cell type
responsible for cross-priming—acquire
endogenous antigens from infected cells
in the periphery, and then migrate to
the lymph nodes where they display
antigenic  peptides in association with
MHC class I molecules. MHC class
I–peptide complexes are recognized by
antigen-specific CTLs, which become
activated and expand in response to
antigen recognition (5). In this scenario,
the source of antigens (intracellular, but
from a different cell, or extracellular as
in vaccination settings) is distinct from
that usually sampled by the classical
MHC class I antigen presentation path-
way (intracellular antigens within the
antigen presenting cell). Hence the
mechanism of antigen degradation and
delivery of the peptide to MHC class I
molecules is also likely to be different.
The mechanism of cross-presentation
has garnered much interest in recent
years, in part because cross-presentation
is likely to be important in activating
CTLs in response to vaccine antigens.
But the mechanism (or mechanisms)
has yet to be definitively defined.
 
Deciphering mechanism
 
There are many difficulties inherent in
defining the mechanism of cross-presen-
tation. One is the source of antigen. In
vaccine studies, heat shock proteins
(such as gp96), apoptotic bodies, the
content of late endosomes (exosomes),
cell lysates, intact cells, peptides, anti-
bodies, and bead-associated proteins have
all been used as sources of antigen (3).
Most of these antigens are extracellular
but are derived from an intracellular
source (the infected cell) and are likely
liberated as a result of cell lysis. But in-
tracellular antigens from intact cells can
also be cross-presented. One way this
could occur is through the swapping of
intracellular peptides through gap junc-
tions (6). It has been known for a long
time that most tissue cells are electri-
cally coupled with their neighboring
cells through gap junctions, small chan-
nels that connect the cytosols of adjacent
cells. Dendritic cells and activated mono-
cytes can also establish gap junctions
with other cells—including infected
cells—and thereby acquire antigenic
fragments for cross-presentation (6).
Notably, tumors usually close their gap
junctions, opting to live solitary lives.
This may explain why tumors often
elicit poor CTL responses. Still, this
immunological coupling through gap
junctions could explain cross-presenta-
tion under conditions in which the an-
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tigen-expressing cell does not release
the antigen into the extracellular milieu.
Coupling of antigen-containing cells
and APCs by gap junctions does not,
however, explain how extracellular an-
tigens, such as those used in vaccina-
tion studies, are cross-presented. Previ-
ous studies with a variety of extracellular
antigens have demonstrated crucial roles
for TAP (7) and the proteasome (8, 9) in
cross-presentation. One interpretation
of these results is that these antigens (or
peptides derived thereof) somehow en-
ter the cytosol of DCs, making them
available for proteasomal degradation,
transport into the ER, and presentation
on MHC class I molecules. Another
possibility lies in the observation that
MHC class I molecules can be recycled
from the cell surface along the endocytic
MHC class II pathway and exchange
endogenous for exogenous peptides en
route (10). Notably, TAP and protea-
some activities are both required for sur-
face expression of MHC class I mole-
cules (11), without which the recycling
pool cannot exist. Hence, the involve-
ment of TAP or proteasomes in cross-
presentation is not necessarily evidence
for entry of exogenous antigens into the
cytosol of DCs, but it also does not ex-
clude this possibility. Recent studies re-
vealed a role for a putative endocytosis
signal in MHC class I (12) and for endo-
somal proteases (13) in cross-presenta-
tion, which support a role for the recy-
cling pathway. In this model, antigens
would be degraded by endocytic pro-
teases rather than the proteasome, and
thus some antigens that would normally
be presented in the classical pathway
might not survive to be cross-presented.
Figure 1. Various models of cross-presentation. In the classical 
MHC class I antigen–presenting pathway, intracellular antigens are 
degraded by the proteasome and peptidases. A fraction of the resulting 
peptides associate with TAP in the ER membrane where newly synthe-
sized MHC class I molecules are arrested until loaded with peptide. MHC 
class I–peptide complexes then leave the ER and are transported to the 
plasma membrane. Extracellular antigens can enter this pathway in 
various ways. (A) Gap junctions allow direct transfer of peptides from 
infected cells into the cytosol of DCs. (B) MHC class I molecules can 
enter the recycling pathway and exchange peptides. (C) ER components 
become an integral part of the phagosomal pathway. The ERAD pathway 
then exports exogenous antigen from the phagosome into the cytosol 
and phagosomal TAP allows retro-transport of peptides back into the 
phagosome. (D) Exogenous antigens can be transported over the endoso-
mal membrane. (E) Exosomes secreted by infected cells can bind to DCs 
for cross-presentation.
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Other mechanisms besides the recy-
cling pathway might also result in cross-
presentation (Fig. 1). For example,
exosomes—vesicles derived from the
interior of endocytic structures that are
released by many cell types—can also
induce CTL responses by cross-presen-
tation (14). Whether simple binding of
these small vesicles, which contain
MHC class I–peptide complexes, to the
plasma membrane of DCs suffices to
trigger CTL activation is unclear and
the mechanism is still poorly defined.
In addition, various experiments have
shown that extracellular proteins can be
transferred from endosomes into the
cytosol of DCs (9), although how this
occurs is unclear. It might involve dis-
solution of the endocytic membrane or
specific protein transporters that pump
the antigen out of endosomes and/or
lysosomes. Note that solubilization of
an antigen-containing endocytic struc-
ture would liberate endosomal proteases
and likely result in the death of the
cross-presenting cell.
 
ER–phagosome model
 
Recently, at least three papers offered
an alternative model of cross-presenta-
tion: direct fusion of phagosomes with
the ER membrane. In other words,
they propose that the phagosomal
membrane is formed—entirely or in
part—from the ER membrane. As a
consequence of this fusion, the enzy-
matic machinery required for the re-
lease of phagosomal proteins into the
cytosol (the ER-associated degradation
[ERAD] system) and the MHC class I
loading machinery become an integral
part of the endocytic system (15, 16).
The ERAD system, which shuttles
misfolded proteins from the ER into
the cytosol for proteasomal degrada-
tion, would thus become the phago-
some-to-cytosol protein transporter
mentioned earlier. This model offers a
new mechanistic explanation for MHC
class I cross-presentation, but has re-
cently been tested and refuted (1).
Moreover, we suggest that this model
is problematic for other reasons and is
thus unlikely to contribute significantly
to cross-presentation in vivo.
Early studies of bacteria that live
and propagate in phagosomes suggested
that the phagosomal membrane was
largely derived from the plasma mem-
brane, with a minor contribution from
other endocytic structures including
late endosomes, lysosomes, and MIICs
(vesicles that accumulate MHC class II
molecules) (17). But more recent stud-
ies—most of which used synthetic
beads as a substitute for antigen—found
ER-specific proteins such as calnexin,
calreticulin, and the ERAD translocon
subunit Sec61p in the isolated bead-
containing fractions (18). Based on this
finding, the authors concluded that
the membrane of the bead-containing
phagosome (beadosome) was derived,
at least in part, from the ER mem-
brane. But these results could also be
explained by contamination of the be-
adosome membrane with ER-derived
vesicles during purification.
Electron microscopy has also been
used to show that the phagosomal
membrane is formed from the ER.
Gagnon et al. showed that the ER
membrane and the plasma membrane
fused at the site of bead contact (18).
However, in that study the content of
the ER lumen did not diffuse into the
extracellular medium and membrane-
like structures that separated the ER
from the phagocytic cup were still visi-
ble, suggesting the possibility that bona
fide fusion did not occur. The authors
also noted that an ER-specific enzy-
matic activity (glucose-6-phosphatase
[G6Pase]) was detected in the beado-
some. Since then, several new isotypes
of G6Pase have been identified, only
one of which contains an ER retention
motif (19). Thus, it is possible that this
enzyme might be more widely localized
than it was originally thought to be.
Despite these caveats, the concept
that the ER contributes to the phago-
somal membrane is highly attractive as
it provides a mechanistic explanation
for the cross-presentation of extracellu-
lar proteins. More recently, two papers
were published claiming that this route
was operational when antigens were
given in association with 3-
 
 
 
m beads
(15, 16). Whether other antigen cock-
tails utilize the same pathway was not
addressed. These studies also failed to
satisfactorily address the underlying is-
sue of ER contamination, which ren-
ders the localization of ER-specific
markers (such as Sec61, TAP, tapasin,
calreticulin, and Erp57) in purified
bead-containing vesicles open to alter-
native interpretations. Indeed, Guer-
monprez et al. used cryo-electron mi-
croscopy to detect the ER marker
calreticulin directly by antibodies (10).
They failed to detect these at the
phagosomal membrane but only “in
close apposition” in the ER.
In the study by Houde et al., the
proteasome and undefined polyubiq-
uitinated proteins were coisolated with
the beadosome, and this resulted in a
rather eccentric model (16). In this
model, the bead-associated antigens
are pumped from the beadosome into
the cytosol by the Sec61-containing
ERAD system (20) and are ubiqui-
tinated by beadosome-associated en-
zymes during retrotranslocation. In a
sort of a coupled reaction, the ret-
rotranslocated antigens are degraded by
the beadosome-associated proteasome,
and the resulting peptide fragments as-
sociate exclusively with TAP com-
plexes located in the beadosome. If
correct, this suggests that the physical
laws for Brownian motion do not ap-
ply to bead-derived antigens since they
and their degradation products “know”
where to be targeted to: beadosome-
associated proteasomes and TAP, respec-
tively. Ackerman et al. used another
approach to test the feasibility of direct
fusion of the ER to bead-containing
phagosomes (21). They performed the
same type of experiments as discussed
above (with similar problems) but also
showed that a soluble viral TAP inhibi-
tor (US6) could access a macropi-
nocytic compartment and block cross-
presentation of a cointernalized soluble
protein. However, a subsequent paper
by the same authors showed that exog-
enous proteins could follow a retro-
grade transport pathway from endo-
somes, through the Golgi and back
into the ER (22). This suggests that
soluble proteins might be cross-pre-
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sented as a result of their ability to di-
rectly access the MHC class I process-
ing machinery in the ER lumen.
Retrograde transport through the
Golgi could thus explain how soluble
antibodies are able to gain access to the
ER and why soluble US6 inhibits
cross-presentation. In other words, it
does not prove the existence of a
mixed ER–phagosome compartment,
but rather reveals yet another potential
mechanism by which extracellular anti-
gens could be cross-presented.
So does the ER–phagosome exist?
As mentioned earlier, experiments us-
ing bacterial phagosomes suggested that
the plasma membrane rather than the
ER was the primary source of phagoso-
mal membranes (17, 23, 24). In their
new study, Touret et al. rigorously
tested the origin of the phagosomal
membrane around ingested beads or
bacteria (1). The experiments per-
formed in earlier studies (15, 16, 18)
were largely repeated by Touret et al.
Quantitative immunolabeling for ER
markers and G6Pase activity measure-
ments showed no evidence for a contri-
bution of the ER to the phagosomal
membrane. In addition, extracellular
dyes were shown to be constrained in
the phagosome and did not diffuse into
the ER, as would be expected if the
ER–lumen was in (even temporal) con-
tinuum with the forming beadosome.
The authors performed a plethora of
experiments, none of which provided
evidence for ER–phagosome fusion (1).
One experiment deserves special at-
tention because of its elegance. In this
experiment, the biotin-binding pro-
tein avidin was expressed with an ER
retention signal (KDEL) in a macro-
phage cell line. Beads coated with bi-
otin were then phagocytosed by the
cells, and direct contact between the
ER-retained avidin and bead-associ-
ated biotin was quantified. No avidin–
biotin interactions were observed, cast-
ing more doubt on the concept of
direct interaction between the ER and
phagosomes (1). Touret et al. conclude
that the plasma membrane and the en-
docytic pathway are the major sources
for phagosomal membranes, with no
significant contribution by the ER (es-
timated between 0 and 10%) (1).
 
Calculating the odds of ER-phagosome 
fusion
 
The feasibility of this model may be
deduced by “number crunching” ac-
cording to Yewdellian philosophy (25).
An estimation of the numbers of MHC
class I molecules entering a 3-
 
 
 
m bead-
osome (15, 16) from the ER and the
numbers of molecules required to ini-
tiate cross-presentation may help reveal
whether the ER–phagosome fusion
mechanism is plausible. If ER-derived
membrane constituted 10% of the phago-
somal membrane, would this suffice
for efficient cross-presentation? If one
approximates that an average rounded
cell has a radius of 
 
 
 
10 
 
 
 
m, then by
comparing the surface area (4
 
 
 
r
 
2
 
) of
the cell with that of the 3-
 
 
 
m bead-
induced phagosome, one can calculate
that 
 
 
 
2% ([1.5/10]
 
2
 
 or 
 
 
 
2 
 
  
 
10
 
 
 
2
 
) of
the plasma membrane is contributed to
the membrane of the 3-
 
 
 
m beadosome
(radius of 
 
 
 
1.5 
 
 
 
m). The ER consti-
tutes 
 
 
 
60% of cellular lipids (compared
with the plasma membrane’s 5%) (26),
which means that 0.16% (2 · 10
 
 
 
2
 
 
 
 
 
[5/60]) of the ER membrane would be
donated to each beadosome, if the be-
adosome membrane was composed en-
tirely of ER-derived membrane.
MHC class I molecules have a half-
life of over 12 h (although this varies
somewhat in different cell types) but
are available for peptide loading in the
ER for 30 min or less (27). Even with
this conservative estimation, this im-
plies that at every moment less than
100,000 peptide-receptive MHC class I
molecules would be located in the ER
of a DC that contains a total of 2 mil-
lion MHC class I molecules. Of these,
16 (100,000 
 
 
 
 2 · 10
 
 
 
2
 
 
 
 
 
 [5/60] 
 
 
 
0.1) MHC class I molecules would en-
ter one 3-
 
 
 
m phagosome at a 10%
contribution of the ER and 160 mole-
cules at a 100% contribution. These
numbers would decrease ninefold for a
1-
 
 
 
m bead and even more for soluble
antigens and immune complexes.
A minimum of 40 and 400 MHC–
peptide complexes is reported to be re-
quired for stimulation of primed and
naive T cells, respectively (28). Based
on our calculations, T cell activation
would thus occur only if nearly all the
peptides delivered into the cytosol
from bead-derived phagosomes found
their way back into phagosomes with-
out any competition from endogenous
peptides. Given that endogenous pep-
tides are present in the cytoplasm even
before exogenous antigens are de-
graded (2), beadosome-derived anti-
genic peptides would likely be out-
competed by endogenous peptides and
would thus return to the beadosomes
too late to load the few ER-derived
MHC class I molecules at that location.
However, if the ER translocon protein
Sec61, which also inserts polypeptides
into the ER lumen as they are trans-
lated, is introduced in the phagosome,
as suggested by previous studies (15,
16, 18), then translation of novel pro-
teins could continue at the phagosomal
membrane and result in the deposition
of de novo–translated proteins directly
into the phagosome. The phagosome
would thus mimic the ER by allowing
the introduction of nascent proteins
(including MHC class I molecules), but
no data are available on this point.
Our own electron microscopy
analysis shows that typical ribosomal
structures can be found associated to
the ER membrane, but no such struc-
tures were localized to the beadoso-
mal membrane (Fig. 2). Bead-induced
cross-presentation therefore must rely
on the few ER-derived MHC class I
molecules, or on cell surface–derived
MHC class I molecules (2 million 
 
 
 
 2 ·
10
 
 
 
2
 
 
 
 
 
 40,000 surface MHC class I
molecules in a 3-
 
 
 
m beadosome) for
cross-presentation of phagosomal anti-
gens. Surface MHC class I molecules
can efficiently exchange peptides be-
tween pH 4.5 and 5.5 (10), suggesting
that peptide loading could take place in
the phagosomal environment, although
the loading would be considerably less
efficient than in the “specialized”
MHC class I–loading complex in the
ER. However, inefficiency would not
be a major issue in the recycling path-
way as 40,000 surface-derived MHC
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class I molecules would be available to
bind peptides, whereas only 160 MHC
class I molecules would be available if
the beadosome membrane were de-
rived entirely from the ER.
 
Concluding considerations
 
Various studies have reached diametri-
cally opposing conclusions regarding
the origin of the phagosomal mem-
brane—a crucial question underlying
the mechanism of cross-presentation.
Gagnon et al. showed an ER contribu-
tion to the phagosomal membrane in
macrophages, but not in other cells
such as neutrophils (18). These experi-
ments could also not be confirmed in
macrophages and DCs in the recent
study by Touret et al. (1). Although the
studies that argue for the ER–phagoso-
mal fusion mechanism received much
attention, they did not address the
mechanism of cross-presentation of
physiological antigens, including anti-
body-bound antigens (29), soluble an-
tigens (30), and intracellular antigens
(6), which might all follow distinct
pathways of degradation inside the cell.
Furthermore, a simple calculation pre-
dicts that cross-presentation via the
ER–phagosome pathway would be
highly inefficient, if at all possible.
Apart from being an interesting
biological question, cross-presentation
has direct consequences for vaccination
strategies aimed at inducing CTL re-
sponses. These vaccines should be able
to induce potent CTL responses and T
cell memory, and the specificity of the
CTL response will result from the
cross-presentation of antigenic fragments.
Understanding the mechanism(s) of
cross-presentation will help rationalize
vaccine development and improve the
chances to arrive at successful antiviral
and antitumor vaccines.
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